NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $538 | $564 | $748 | $772 |
| Short-Term Investments | $165 | $175 | $60 | $62 |
| Receivables | $20 | $0 | $2 | $21 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $20 | $0 | $0 |
| Total Curr. Assets | $732 | $770 | $817 | $863 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $1 | $1 |
| Long-Term Investments | $53 | $44 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $54 | $45 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $786 | $815 | $818 | $865 |
| Liabilities | – | – | – | – |
| Payables | $4 | $6 | $6 | $5 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $3 | $6 |
| Other Curr. Liab. | $49 | $21 | $30 | $91 |
| Total Curr. Liab. | $58 | $37 | $41 | $107 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $58 | $37 | $41 | $107 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $14 | $14 | $14 | $13 |
| Retained Earnings | $0 | -$615 | -$598 | $0 |
| AOCI | $5 | $4 | $4 | $4 |
| Other Equity | $709 | $0 | $0 | $740 |
| Total Equity | $728 | $778 | $777 | $758 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $786 | $815 | $818 | $865 |
| Net Debt | -$538 | -$564 | -$748 | -$771 |